Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Drugs Added To Sichuan Essential Drug List

This article was originally published in PharmAsia News

Executive Summary

Merck recently announced the addition of its originator drug Zocor to Sichuan province's essential drug list. With the addition of two types of the cardiovascular drug to the list, prices will be cut by more than 50 percent. This is the first foreign originator drug to enter the province's essential drug list, and cardiovascular specialist Zhang Ting-Jie hopes the example set by Merck will influence other drug companies to seek essential drug listing and bring cheap, high-quality drugs to the people. He also notes that cardiovascular disease has become China's most common disease, with more than 1 million hypertensive patients in the Chengdu region alone. (Click Here For More - Chinese Language

You may also be interested in...



Novartis Q4 Preview: Launches Likely To Deliver

Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.

Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine, And Zimmer Biomet Fills Communications Spot

Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.

Big Win For EMA On Transparency

The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.

UsernamePublicRestriction

Register

SC074361

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel